Kinetin riboside
(Synonyms: 激动素核苷; N6-Furfuryladenosine) 目录号 : GC36393
An anticancer nucleoside
Cas No.:4338-47-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Kinetin riboside is a purine derivative and nucleoside with anticancer activity.1 It induces the production of reactive oxygen species (ROS), cellular ATP depletion, and apoptosis in HepG2 cells. Kinetin riboside (10 ?M) reduces cyclin D1 and cyclin D2 levels, as well as induces cell cycle arrest at the G1 phase and apoptosis in patient-derived multiple myeloma cells.2 In vivo, kinetin riboside (85 mg/kg) reduces tumor growth in OCI-My5 and RPMI-8226 myeloma mouse xenograft models.
1.Orlicka-P?ocka, M., Gurda-Wozna, D., Fedoruk-Wyszomirska, A., et al.Circumventing the Crabtree effect: Forcing oxidative phosphorylation (OXPHOS) via galactose medium increases sensitivity of HepG2 cells to the purine derivative kinetin ribosideApoptosis25(11-12)835-852(2020) 2.Tiedemann, R.E., Mao, X., Shi, C.-X., et al.Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activityJ. Clin. Invest.118(5)1750-1764(2008)
|
Cell experiment: |
HeLa and mouse melanoma B16F-10 cells are treated with 5, 10, 20 μM kinetin riboside for 48 h. 15 μL of MTT solution (5 mg/mL) is added to each well and cells are maintained for 4 h at 37°C. Hundred microlitres of solubilizing solution is then added. After an overnight incubation at room temperature, absorbance at 490 nm is measured[2]. |
|
Animal experiment: |
Mice: Male C57BL/6 mice are injected B16 F-10 cells. After 5 days for tumor growth, kinetin riboside (10, 20, 40 mg/kg) is injected to tumor mass directly. Drug injection is performed once a 3 days for three times. After third injection of drug, mice are kept for 3 days with no injection and tumor mass is removed from each mouse and weighed[2]. |
|
References: [1]. Rajabi M, et al. Antiproliferative activity of kinetin riboside on HCT-15 colon cancer cell line. Nucleosides Nucleotides Nucleic Acids. 2012;31(6):474-81. |
|
| Cas No. | 4338-47-0 | SDF | |
| 别名 | 激动素核苷; N6-Furfuryladenosine | ||
| Canonical SMILES | OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NCC4=CC=CO4)O1)O)O | ||
| 分子式 | C15H17N5O5 | 分子量 | 347.33 |
| 溶解度 | DMSO: ≥ 29 mg/mL (83.49 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8791 mL | 14.3955 mL | 28.7911 mL |
| 5 mM | 0.5758 mL | 2.8791 mL | 5.7582 mL |
| 10 mM | 0.2879 mL | 1.4396 mL | 2.8791 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet